Lanfong H Lee

Title: Lanfong H Lee: Innovator in Vaccine Development

Introduction

Lanfong H Lee is a notable inventor based in Silver Spring, MD (US). He has made significant contributions to the field of immunology, particularly in vaccine development. His work focuses on creating effective treatments that mitigate the risks associated with autoimmune responses.

Latest Patents

Lanfong H Lee holds 1 patent. His patent involves a recombinant protein that comprises the maltose binding protein (MBP) fused to amino acids 5–337 of the FlaA flagellin of VC167. This invention has demonstrated immunogenicity and protective efficacy against challenges posed by a heterologous strain of 81–176 in mammals. Additionally, it includes a recombinant DNA construct encoding the immunodominant region (regions I through III) of flagellin from spp. for use as a component of a vaccine against diarrhea. This innovative approach represents an effective treatment while avoiding the induction of Guillain Barre Syndrome (GBS), a post-infection polyneuropathy that has hindered vaccine development in the past.

Career Highlights

Lanfong H Lee is currently associated with the United States Navy, where he contributes his expertise in immunology and vaccine research. His work is crucial in advancing the development of safe and effective vaccines.

Collaborations

Lanfong has collaborated with notable colleagues, including Edward Burg and Trevor J Trust. Their combined efforts in research and development have furthered the understanding of vaccine efficacy and safety.

Conclusion

Lanfong H Lee's innovative work in vaccine development highlights his commitment to improving public health through scientific research. His contributions are paving the way for safer vaccines that can effectively combat infectious diseases.